Astellas Pharma still looks to grow in cancer with a pipeline that includes internally developed programs that could stand out in oncology. But the drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.
The Investor Relations website contains information about AbbVie’s business for stockholders, potential investors, and financial analysts.
Discover the latest news about our company, our products, our policies, and our people.
Adam Colborn, JD, of AMCP, discussed how President Trump’s rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives.
Hone Health’s Series A round included participation from Tribe Capital, PIF, Republic Capital, Vibe VC, Humbition, Hanwha, Gaingels, Looking Glass Capital, FJ Labs and Agent…
Phase 2 data for Cargo Therapeutics’ CD22-targeting cell therapy show low durability and cases of a severe immune response, some that were classified as grade…
Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda…
This article describes the challenges and lessons learned in conducting a major public health campaign to connect immigrant children and their parents to school-required immunizations…
Published on: January 30, 2025 Type 1 diabetes (T1D) can happen to anyone, at any age, regardless of family history. Unfortunately, up to 40% of…
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO ® – exceeding $1.6 billion in revenues,…
As the pool of approved therapies continues to (hopefully) expand, the clinical and diagnostic testing communities need to do a better job at ensuring the…
